Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2016-07-26
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well orteronel works in treating patients with metastatic
hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
University of Southern California
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)